Table 1.
Baseline demographic characteristics of the study patients
| Characteristics | PCC3 (n = 74) | LD rFVIIa (n = 32) | p |
|---|---|---|---|
| Demographics |
|
|
|
| Age (years)* |
73 [62.3-81.0] |
67 [59.5-79.3] |
0.32 |
| M:F |
43:31 |
22:10 |
0.39 |
| Indication for Warfarin, n*,#, **, *** | |||
| Atrial arrhythmia |
44 |
19 |
0.99 |
| Cardiomyopathy |
2 |
1 |
1.00 |
| Valve replacement |
11 |
7 |
0.38 |
| Ischemic CVA |
2 |
2 |
0.58 |
| DVT/PE |
|
|
|
| Treatment*# |
18 |
6 |
0.53 |
| Prophylaxis |
11 |
3 |
0.55 |
| Portal vein thrombosis |
0 |
1 |
0.30 |
| Hyperhomocysteinemia |
1 |
0 |
1.00 |
| Lupus Anticoagulant |
1 |
0 |
1.00 |
| Syndrome |
|
|
|
| Unknown | 1 | 0 | 1.00 |
*2 with Protein S deficiency # 2 with Anticardiolipin Syndrome.
**5 with 2 indications ***5 with 2 indications.
*Data reported as median [IQR].
PCC3, 3 factor prothrombin complex concentrate; LDrFVIIa, low dose recombinant factor VII activated; CVA, cerebral vascular accident; DVT, deep vein thrombosis; PE, pulmonary embolism.